Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telescope InnovationsTELIF 32 3-1 Month Momentum % is -45.57% as of Aug. 20, 2026. GuruFocus rates TELIF with a GF Score™ of 32/100 and a GF Value™ of $0.39 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,386 Biotechnology companies, Telescope Innovations ranks worse than 93.51% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-20), Telescope Innovations's 3-1 Month Momentum % is -45.57%.
The industry rank for Telescope Innovations's 3-1 Month Momentum % or its related term are showing as below:
TELIF's 3-1 Month Momentum % is ranked worse than 93.51% of 1386
companies
in the Biotechnology industry
Industry Median: -5.39
vs TELIF: -45.57
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Telescope Innovations 3-1 Month Momentum % Related Terms
TELIF vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Telescope Innovations's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telescope Innovations (TELIF) has a 3-1 Month Momentum % of -45.57% as of Aug. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Telescope Innovations and its competitors. According to the industry distribution chart, Telescope Innovations ranks #1296 out of 1386 companies in the Biotechnology industry, placing it in the top 93.5%.
Is Telescope Innovations' 3-1 Month Momentum % too high?
Telescope Innovations' current 3-1 Month Momentum % is -45.57%. Based on the distribution chart, Telescope Innovations ranks #1296 out of 1386 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telescope Innovations has a GF Score™ of 32/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #1296 out of 1386 companies for 3-1 Month Momentum %. This places Telescope Innovations in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Telescope Innovations and its competitors. Telescope Innovations's current 3-1 Month Momentum % is -45.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.39, compared to a current price of $0.33 — trading 16.7% below its estimated fair value. The current 3-1 Month Momentum % is -45.57%. Telescope Innovations' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current 3-1 Month Momentum % is -45.57% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be undervalued.
The current stock price of $0.33 is trading 16.7% below its estimated GF Value™ of $0.39.
GuruFocus considers Telescope Innovations to be Modestly Undervalued.
Key valuation signals for TELIF:
3-1 Month Momentum %: -45.57%
GF Value™: $0.39 vs. price of $0.33 (16.7% below fair value)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
32GF Score
Get the complete analysis for TELIF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
